Denny Kraichely, PhD, principal research scientist and group leader of pharmaceutical development and marketed product support at Centocor R&D, Inc. (Radnor, PA), a Johnson & Johnson Company, has joined the Editorial Advisory Board of BioPharm International.
Denny Kraichely, PhD, principal research scientist and group leader of pharmaceutical development and marketed product support at Centocor R&D, Inc. (Radnor, PA), a Johnson & Johnson Company, has joined the Editorial Advisory Board of BioPharm International.
At Centocor, Kraichely plays a very active role in identifying, evaluating, and implementing innovative technologies to support an ambitious research and development pipeline. Before joining Centocor in late-2001, he was a molecular biologist in cardiovascular discovery research at Procter and Gamble Pharmaceuticals (Cincinnati, OH). Kraichely received a PhD in Pharmacological and Physiological Science from Saint Louis University (1995–1999), and was a post-doctoral fellow in the Departments of Molecular Integrative Physiology and Cell Structural Biology at the University of Illinois at Urbana-Champaign (1999-2000). Over the past decade, he has authored 16 manuscripts in peer-reviewed journals and review chapters and has presented data at 40 scientific research conferences.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.